Product image of Klisyri (Tirbanibulin) supplied by GNH India

Klisyri

Active Ingredient:
Tirbanibulin
Origin:
EU

Klisyri (Tirbanibulin)

Tirbanibulin, the active ingredient in Klisyri, is a Src kinase inhibitor presented as a 1% topical solution for topical use. It is indicated for the field‑directed treatment of actinic keratosis on the face and scalp in adult patients, providing a non‑surgical option to remove precancerous skin lesions and reduce the risk of progression to invasive cancer.

GNH India supplies Klisyri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution across EU and other regulated markets while adhering to stringent regulatory standards.

Manufacturer / TM Owner

Almirall, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Klisyri (tirbanibulin) is a topical antineoplastic agent used in the management of actinic keratosis, a precancerous skin condition.

  • Actinic keratosis (face and scalp): clears precancerous lesions and lowers the likelihood of progression to squamous cell carcinoma.

How It Works

  • Tirbanibulin inhibits Src tyrosine kinase activity and interferes with tubulin polymerization in abnormal keratinocytes. This dual action halts cell‑cycle progression, induces G2‑M arrest, and triggers apoptosis of dysplastic epidermal cells, leading to lesion regression without systemic exposure.

Side Effects

Klisyri may cause local skin reactions that are generally mild to moderate.

Common Side Effects

  • Erythema: redness at the application site.
  • Crusting: formation of dry scabs.
  • Scaling: flaking of treated skin.
  • Itching: mild to moderate pruritus.
  • Pain or burning: transient discomfort.
  • Dryness: reduced skin moisture.

Serious or Rare Side Effects

  • Severe allergic reaction: swelling, hives, or difficulty breathing.
  • Contact dermatitis: intense irritation or rash.
  • Secondary infection: signs of bacterial or fungal involvement.
  • Ulceration: breakdown of skin tissue.
  • Persistent edema: prolonged swelling.
  • Systemic hypersensitivity: rare systemic immune response.

Precautions & Warnings

Before prescribing Klisyri, clinicians should consider patient‑specific factors and monitor for adverse reactions.

  • Contraindication: Known hypersensitivity to tirbanibulin or any excipient.
  • Application area: Avoid use on broken, inflamed, or infected skin.
  • Mucosal surfaces: Do not apply to eyes, mouth, or genital mucosa.
  • Pregnancy and lactation: Safety not established; use only if benefit outweighs risk.
  • Pediatric use: Not established; limited to adult patients.
  • Store below 25°C: keep in the original container, protect from light and moisture.

Avoid Interactions

Topical tirbanibulin has limited systemic drug‑interaction potential, but co‑administration with certain agents may affect tolerability.

Major Interactions (Avoid)

  • Concurrent use of other topical antineoplastic agents on the same area: increased risk of severe skin toxicity.
  • Known allergy to formulation components: may trigger severe dermatitis.

Moderate Interactions (Monitor Closely)

  • Co‑application with keratolytic agents (e.g., salicylic acid): may enhance irritation.
  • Use with topical corticosteroids: could mask early signs of adverse skin reactions.
  • Photosensitizing drugs (e.g., tetracyclines): may increase sun‑induced skin sensitivity.
  • Systemic immunosuppressants: monitor for delayed wound healing.
  • Over‑the‑counter moisturizers containing irritants: assess for additive irritation.

Frequently Asked Questions

Klisyri is a prescription topical solution containing tirbanibulin that is used to treat actinic keratosis on the face and scalp. It works by removing precancerous skin lesions, helping to prevent progression to invasive skin cancer.

Tirbanibulin blocks Src tyrosine kinase activity and disrupts tubulin polymerization in abnormal keratinocytes. This dual inhibition stops cell‑cycle progression, induces apoptosis, and leads to the clearance of actinic keratosis lesions.

The prescribed dose of Klisyri is determined by the treating physician. Typically, a thin layer is applied to the affected area once daily for a defined treatment period, but the exact regimen should follow the prescriber’s instructions.

Safety of tirbanibulin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

To order Klisyri, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Klisyri offers a non‑surgical, field‑directed approach that differs from cryotherapy or topical 5‑fluorouracil. Its Src kinase inhibition provides targeted lesion clearance with a short treatment course, whereas other agents may require longer applications or cause broader skin irritation.

Store Klisyri below 25 °C in its original container, protected from light and moisture. Keep the product out of reach of children and avoid freezing. Do not use the solution after the expiration date printed on the label.

Klisyri is applied topically to clean, dry skin. A thin layer should be spread over the affected area of the face or scalp once daily, as directed by the prescriber, and left in place for the prescribed treatment duration.

Serious risks include severe allergic reactions such as anaphylaxis, extensive contact dermatitis, secondary skin infection, and ulceration of the treated area. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, or rapidly worsening skin lesions.

Klisyri should not be used by individuals with known hypersensitivity to tirbanibulin or any formulation excipients, on broken or infected skin, or on mucosal surfaces. It is also not recommended for patients where safety in pregnancy or lactation cannot be assured.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tirbanibulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT